Matilda Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.15 Cr
- Revenue Growth -5.84%
- Profit Growth -9.24%
- Ebitda -2.54%
- Net Worth 15.27%
- Total Assets 1.30%
About Matilda Pharmaceuticals (India)
Matilda Pharmaceuticals (India) Private Limited (MPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 July 2014 and has a history of Ten years and seven months. Its registered office is in Sindhudurg, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.15 Cr.
Sameer Navare and Virendra Nachane serve as directors at the Company.
Company Details
- Location
Sindhudurg, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24200PN2014PTC151822
- Company No.
151822
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jul 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Matilda Pharmaceuticals (India)?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sameer Navare  | Director | 15-Jul-2014 | Current |
| Virendra Nachane | Director | 15-Jul-2014 | Current |
Financial Performance of Matilda Pharmaceuticals (India).
Matilda Pharmaceuticals (India) Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 5.84% decrease. The company also saw a slight decrease in profitability, with a 9.24% decrease in profit. The company's net worth Soared by an impressive increase of 15.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Matilda Pharmaceuticals (India)?
In 2021, Matilda Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹11.48 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.90 Cr
- Uco Bank : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Feb 2018 | Others | ₹0.50 M | Open |
| 06 Feb 2018 | Others | ₹8.48 M | Open |
| 27 Jun 2016 | Uco Bank | ₹2.50 M | Open |
How Many Employees Work at Matilda Pharmaceuticals (India)?
Unlock and access historical data on people associated with Matilda Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Matilda Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Matilda Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.